Black checkmark with a sparkle and a curved line underneath on a white background.
Company

CalciMedica, Inc.

Ticker
CALC
Sector
Industry
Report date
November 11, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include a reverse stock split, widened Q2 losses, insider buying activity, and updates on clinical trial progress and halts.

Recent developments:
  • CalciMedica announced a 1-for-5 reverse stock split in August 2026 [N1].
  • The company reported a widened net loss in Q2 2026 and indicated a planned Phase 1b Auxora readout in mid-2027 [N2].
  • Insider buying activity was reported in June 2026, reflecting purchases by company insiders [N3].
  • The KOURAGE Phase 2 trial was halted following safety concerns related to mortality imbalance, with no plans to resume dosing [N4].
  • CalciMedica is prioritizing other development programs including a planned Phase 1b study of Auxora in pulmonary hypertension [N4].
  • The company has been highlighted as a stock to watch due to its clinical pipeline and development activities [N5].
  • Insider purchases and clinical trial speculation have been topics of recent market commentary [N6][N7][N8].
Overview

CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company with a focus on developing novel therapies targeting inflammatory and pulmonary diseases. The company’s lead product candidate, Auxora, has been evaluated in Phase 2 clinical trials for acute pancreatitis, COVID-19 pneumonia with ARDS, and acute kidney injury with associated respiratory failure. The KOURAGE Phase 2 trial was halted due to safety concerns. CalciMedica is planning a Phase 1b proof-of-concept study of Auxora in pulmonary hypertension and is developing CM5480, a proprietary oral small-molecule CRAC channel inhibitor for pulmonary hypertension, currently in nonclinical development. The company has not generated revenue and has a history of net losses. As of September 30, 2026, it held $13.8 million in cash and short-term investments, with liquidity ratios indicating a strong short-term financial position. The company’s operations are financed through equity, debt, and loan agreements with covenants that restrict certain activities. The board comprises experienced professionals from biotechnology, pharmaceutical, and financial sectors.

Executive summary

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and pulmonary diseases. The company has no approved products and has never generated revenue from product sales. Its lead candidate, Auxora, has undergone multiple Phase 2 trials, including in acute pancreatitis and COVID-19 pneumonia, with a paused Phase 2 trial (KOURAGE) due to safety concerns. The company is advancing a Phase 1b study of Auxora in pulmonary hypertension and developing CM5480, a small-molecule inhibitor for the same indication. As of September 30, 2026, CalciMedica held approximately $13.8 million in cash and short-term investments, with a strong liquidity position but an accumulated deficit of $193.7 million and ongoing net losses. The company has disclosed risks related to its limited operating history, need for additional capital, and uncertainties in clinical development. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for CALC

Bull case model:

CalciMedica’s advancement of Auxora through multiple Phase 2 trials and planned Phase 1b study in pulmonary hypertension demonstrates active pipeline progression. The company’s strong liquidity position as of September 2026 supports ongoing clinical development activities into mid-2027. Experienced leadership and board members with backgrounds in biotechnology and finance provide governance strength. Insider buying activity indicates some confidence in the company’s prospects. The company’s focus on novel mechanisms for inflammatory and pulmonary diseases addresses significant unmet medical needs.

Bear case model:

CalciMedica has a limited operating history with no approved products or revenue, and a substantial accumulated deficit. The halted KOURAGE trial due to safety concerns highlights clinical development risks. The company’s liquidity, while sufficient into mid-2027, is not adequate to complete regulatory approval or commercialization, necessitating additional capital raises that may dilute shareholders and impose operational restrictions. The loan agreement includes covenants that limit financial and operational flexibility. Clinical and regulatory uncertainties, combined with the need for substantial funding, present significant risks to business continuity and growth.

Moat:

CalciMedica’s moat is primarily based on its proprietary product candidates targeting inflammatory and pulmonary diseases, including Auxora and CM5480. The company’s clinical-stage pipeline and intellectual property portfolio provide potential differentiation. However, as a clinical-stage biopharmaceutical company with no approved products or revenue, its competitive position depends heavily on successful clinical development, regulatory approvals, and eventual commercialization. The company’s specialized focus on CRAC channel inhibitors and inflammatory pathways may offer a niche advantage if clinical efficacy and safety are demonstrated.

Risks overview
Risks summary
The most significant risks for CalciMedica stem from its limited operating history, ongoing net losses, need for substantial additional capital, clinical trial uncertainties including halted studies, and restrictive loan covenants that may constrain operational flexibility.
Risks details:

• Limited Operating History and No Revenue: CalciMedica has never generated revenue from product sales and has a history of net losses, which may make it difficult to assess future viability.
• Need for Additional Capital: The company’s liquidity is sufficient only into the second half of 2027, requiring substantial additional funding to complete development and commercialization.
• Clinical Development Risks: Safety concerns led to halting the KOURAGE trial, and future clinical trials may face delays, negative outcomes, or regulatory challenges.
• Loan Agreement Restrictions: The loan agreement includes covenants restricting financial and operational flexibility, which could limit business opportunities and increase risk of default.
• Dilution and Financing Risks: Raising capital through equity or debt may dilute existing shareholders and impose restrictive covenants or unfavorable terms.

FINAL FORECAST FOR CALC

Final take one line
CalciMedica is a clinical-stage biopharmaceutical company with a well-documented pipeline and financial position but faces significant risks related to clinical development and capital needs.
Final take 12 to 24 month view

Business trends: Continued clinical development of Auxora and CM5480 with focus on pulmonary hypertension and inflammatory diseases; prioritization of pipeline programs following trial halts.
Execution milestones: Planned Phase 1b Auxora study readout mid-2027; IND submission for CM5480 anticipated mid-2027; management of capital resources to sustain operations.
Key risks: Clinical trial safety and efficacy uncertainties; need for substantial additional financing; operational restrictions from loan covenants; potential dilution from capital raises.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates for inflammatory and pulmonary diseases.
  • The company has no products approved for commercial sale and has never generated revenue from product sales.
  • CalciMedica's lead product candidate is Auxora, which has completed Phase 2b trials in acute pancreatitis (AP) and COVID-19 pneumonia with ARDS, and a Phase 2 trial called KOURAGE in acute kidney injury (AKI) and acute hypoxemic respiratory failure (AHRF).
  • Enrollment in the KOURAGE trial was paused in January 2026 due to safety concerns related to mortality imbalance, and the company currently has no plans to resume dosing in this trial.
  • CalciMedica plans a Phase 1b proof-of-concept study of Auxora in pulmonary hypertension (PH), with data anticipated by mid-2027.
  • The company is developing CM5480, a proprietary oral small-molecule CRAC channel inhibitor for PH, currently in nonclinical development with IND submission anticipated by mid-2027.
  • As of September 30, 2026, CalciMedica had cash and cash equivalents of $4.57 million and short-term investments of $9.19 million, totaling approximately $13.8 million in liquid assets.
  • The current ratio as of September 30, 2026, was 4.96, and the cash ratio was 4.8, indicating strong short-term liquidity.
  • The company reported a net loss of $1.67 million for the third quarter ended September 30, 2026, and an accumulated deficit of $193.7 million as of that date.
  • CalciMedica has a loan agreement with Avenue Venture Opportunities Fund II, L.P. providing growth capital, with covenants that restrict certain financial and operational activities.
  • The company has a history of net losses and anticipates incurring significant losses in the future as it advances clinical development.
  • CalciMedica's board of directors consists of seven members with extensive experience in biotechnology, pharmaceuticals, and finance.
  • The company announced a 1-for-5 reverse stock split in August 2026.
  • Insider buying activity has been reported, including purchases by directors.
  • The company halted the KOURAGE trial following safety concerns and is prioritizing other development programs.
  • CalciMedica's liquidity is sufficient to fund operations into the second half of 2027, including the planned Phase 1b Auxora study and IND submission for CM5480, but not sufficient to complete regulatory approval or commercialization of product candidates.
  • The company may need to raise substantial additional capital to complete development and commercialization of its product candidates.
  • Risks include the limited operating history, ongoing losses, need for additional financing, potential dilution from capital raises, and uncertainties related to clinical trial outcomes and regulatory approvals.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-08-27 | www.nasdaq.com | CalciMedica Announces 1-for-5 Reverse Stock Split | https://www.nasdaq.com/articles/calcimedica-announces-1-5-reverse-stock-split
  • N2 | 2026-08-13 | www.nasdaq.com | CalciMedica's Q2 Loss Widens; Phase 1b Auxora Readout In Mid-'27 | https://www.nasdaq.com/articles/calcimedicas-q2-loss-widens-phase-1b-auxora-readout-mid-27
  • N3 | 2026-06-29 | www.nasdaq.com | Monday 6/29 Insider Buying Report: ADBE, CALC | https://www.nasdaq.com/articles/monday-6-29-insider-buying-report-adbe-calc
  • N4 | 2026-01-30 | www.nasdaq.com | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | https://www.nasdaq.com/articles/weekly-buzz-intellia-gets-fda-nod-attrv-pn-trial-apreas-apr-1051-paces-calc-halts-kourage
  • N5 | 2026-01-21 | www.nasdaq.com | Why CalciMedica Is A Stock To Watch | https://www.nasdaq.com/articles/why-calcimedica-stock-watch
  • N6 | 2025-08-19 | www.nasdaq.com | Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks | https://www.nasdaq.com/articles/buy-sell-or-hold-insiders-pile-these-3-healthcare-stocks
  • N7 | 2025-07-19 | www.nasdaq.com | CalciMedica, Inc. Stock (CALC) Opinions on Clinical Trial Speculation | https://www.nasdaq.com/articles/calcimedica-inc-stock-calc-opinions-clinical-trial-speculation
  • N8 | 2025-07-18 | www.nasdaq.com | Insider Purchase: Director at $CALC Buys 4,500 Shares | https://www.nasdaq.com/articles/insider-purchase-director-calc-buys-4500-shares
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine